9.125"

08/2023

Width: 17.0" Length: 18.75" Fold: 1.25" x 1.25"

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use FLUOXETINE CAPSULES, safely and effectively. See full prescribing information for FLUOXETINE CAPSULES. FLUOXETINE capsules, for oral use

Initial U.S. Approval: 1987

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

- See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antide-
- Monitor for worsening and emergence of suicidal thoughts and behaviors (5.1).
 When using fluxatine and olanzapine in combination, also refer to Boxed Warning section of the package insert for Symbyax.

- Fluxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) (1) Acute and maintenance treatment of Dosessive Compulsive Disorder (OCD) (1) Acute and maintenance treatment of Bulimia Nervosa (1)
- Acute treatment of Panic Disorder, with or without agoraphobia (1)
- Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder (1) Treatment Resistant Depression (1)

---- DOSAGE AND ADMINISTRATION-

Indication	Adult	Pediatric
MDD (2.1)	20 mg/day in am (initial dose)	10 to 20 mg/day (initial dose)
OCD (2.2)	20 mg/day in am (initial dose)	10 mg/day (initial dose)
Bulimia Nervosa (2.3)	60 mg/day in am	
Panic Disorder (2.4)	10 mg/day (initial dose)	
Depressive Episodes Associated with Bipolar I Disorder (2.5)	Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose)	Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose)
Treatment Resistant Depression (2.6)	Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose)	

A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with

- A lower of less frequent ossage should be used in patients with nepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications (2.7)
 Fluoxetine capsules and olanzapine in combination:
 Dosage adjustments should be made with the individual components according to efficacy and tolerability (2.5, 2.6)
 Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder or treatment resistant depression (2.5, 2.6)
 Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults (2.5, 2.6)
- Safety of the coadministration of doses above 10 mg olarizapine with 75 mg fluoxetine has not been evaluated in about 5 (2.5, 2.6)
 Safety of the coadministration of doses above 12 mg olarizapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 (2.5)
- --- DOSAGE FORMS AND STRENGTHS--• Capsules: 10 mg, 20 mg, and 40 mg (3)
- --CONTRAINDICATIONS--Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine. Do not use fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start fluoxetine in a patient who is being treated with linezolid or intravenous
- nethylene blue (4.1)
- memplene blue (4, 1)
 Pimozide: Do not use. Risk of QT prolongation and drug interaction (4.2, 5.11, 7.7, 7.8)
 Thioridazine: Do not use. Risk of QT interval prolongation and elevated thioridazine plasma levels. Do not use thioridazine within 5 weeks of discontinuing fluxwetine (4.2, 5.11, 7.7, 7.8)
 When using fluxwetine and olanzapine in combination, also refer to the Contraindications section of the package insert for Symbyax (4)

- -WARNINGS AND PRECAUTIONS Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults: Monitor for clinical worsening and suicidal
- thinking and behavior (5.1) Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including fluoxetine, both whe
- Servician Syndrome, but especially when co-administered with other servicine gia and the service security and the security of the security of
- Allergic Reactions and Rash: Discontinue upon appearance of rash or allergic phenomena (5.3) Activation of Mania/Hypomania: Screen for Bipolar Disorder and monitor for mania/hypomania (5.4) Seizures: Use cautiously in patients with a history of seizures or with conditions that potentially lower the seizure
- Unreshold (5.5) Altered Appetite and Weight: Significant weight loss has occurred (5.6) Increased Risk of Bleeding: May increase the risk of bleeding. Use with NSAIDs, aspirin, warfarin, or other drugs that affect coagulation may potentiate the risk of gastrointestinal or other bleeding (5.7) Angle-Closure Glaucoma: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles
- treated with antidepressants (5.8) Hyponatremia: Has been reported with fluoxetine in association with syndrome of inappropriate antidiuretic hormone
- (SiADH). Consider discontinuing if symptomatic hyponatremia occurs (5.9) Anxiety and Insomnia: May occur (5.10)
- Protectly and insorting web vectors (0.10) OT Prolongation: OT prolongation and ventricular arrhythmia including Torsades de Pointes have been reported with fluoxetine use. Use with caution in conditions that predispose to arrhythmias or increased fluoxetine exposure. Use cautiously in patients with risk factors for OT prolongation (4.2, 5.11) Potential for Cognitive and Motor Impairment: Has potential to impair judgment, thinking, and motor skills. Use caution when exercise of 5.10)
- Potential for Cognitive and Motor Impairment: Has potential to Impair juogment, miniking, and motor skulls, use cau when operating machinery (5.13)
 Long Half-Life: Changes in dose will not be fully reflected in plasma for several weeks (5.14)
 Fluoxetine and Olanzapine in Combination: When using fluoxetine and olanzapine in combination, also refer to the Warnings and Precautions section of the package insert for Symbyax (5.16)
 Sexual Dysfunction: Fluoxetine may cause symptoms of sexual dysfunction (5.17)

- ----ADVERSE REACTIONS --Most common adverse reactions (\geq 5% and at least twice that for placebo) associated with:

Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia, and Panic Disorder: abnormal dreams, abnormal ejaculation, anorexia, anxiety, asthenia, diarrhea, dry mouth, dyspepsia, flu syndrome, impotence, insomnia, libido decreased, nausea, nervousness, pharyngitis, rash, sinusitis, somnolence, sweating, tremor, vasodilatation, and yawn (6.1)

Fluoxetine and olanzapine in combination – Also refer to the Adverse Reactions section of the package insert for Symbyax (6) To report SUSPECTED ADVERSE REACTIONS, contact ScieGen Pharmaceuticals Inc at 1-855-724-3436 or FDA at

1-800-FDA-1088 or www.fda.gov/medw --- DRUG INTERACTIONS

- Monoamine Oxidase Inhibitors (MAOIs): (2.9, 2.10, 4.1, 5.2) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (5.2, 7.7) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam increased 1½, alprazolam further psychomotor performance decrement due to increased levels (7.7)
- evels (7.7)
- levels (7.7) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.7) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.7)
- Serotonergic Drugs: (2.9, 2.10, 4.1, 5.2) Drugs that Interfere with Hemostasis (e.a. Drugs that Interfere with Hemostasis (e.g. NSAIDs, Aspirin, Warfarin): May potentiate the risk of bleeding (7.4) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.6, 7.7) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for Surphysical (7.2)
- Drugs that Prolong the QT Interval: Do not use fluoxetine with thioridazine or pimozide. Use with caution in combination with other drugs that prolong the QT interval (4.2, 5.11, 7.7, 7.8)

Pediatric Use: Safety and effectiveness of fluoxetine in patients < 8 years of age with Major Depressive Disorder and < 7 years of age with 0CD have not been established. Safety and effectiveness of fluoxetine and olanzapine in combination in patients < 10 years of age for depressive episodes associated with Bipolar I Disorder have not been established (8.4) *Hepatic Impairment:* Lower or less frequent dosing may be appropriate in patients with cirrhosis (8.6)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: SUICIDAL THOUGHTS AND BEHAVIORS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Major Depressive Disorder 2.3 Builmia Nervosa 2.4 Paria Disorder 2.5 Fluxwetine and Olanzapine in Combination: Depressive Episodes Associated with Bipolar I Disorder 2.6 Fluxwetine and Olanzapine in Combination: Treatment Resistant Depression 2.7 Dosing in Specific Populations 2.8 Discontinuation of Treatment 2.9 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders 2.10 Use of Fluxwetine with Other MAOIs such as Linezolid or Methylene Blue 3 DOSAGE FORMS AND STRENGTHS 4 OUTRAINDICATIONS 4.1 Monoamine Oxidase Inhibitors (MAOIs) 4.2 Other Contraindications 5 Swartning Exercise 5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults 5.2 Serotonin Syndrome 5.3 Allergic Reactions and Rash 5.4 Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypomania 5.5 Serures 5.6 Altered Appetite and Weight 5.7 Increased Risk of Bleeding 5.8 Angle-Closure Glaucoma 5.9 Hyponatremia	6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Monoamine Oxidase Inhibitors (MAOI) 7.2 CNS Acting Drugs 7.3 Other Serotonergic Drugs 7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDS, Aspirin, Warfarin) 7.5 Electroconvulsive Therapy (ECT) 7.6 Potential for Other Drugs to affect Fluoxetine 7.7 Potential for Other Drugs to affect Fluoxetine 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 9 DRUG ABUSE AND DEPENDENCE 9.3 Dependence 10 OVENDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.4 Specific Populations 13 MONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14.1 Major Depressive Disorder 14.3 Bulimia Nervosa 14.4 Panic Disorder 15.1 How Supplied 16.1 How Supplied 16.1 How Supplied 16.1 How Supplied 16.1 How Supplied 16.2 Botagenesis, Mutagenesis, Impairment of Fertility 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology 14.1 Major Depressive Disorder 14.3 Bulimia Nervosa 14.4 Panic Disorder 15.1 How Supplied 16.1 How Supplied 16.1 How Supplied 16.1 How Supplied 16.1 How Supplied 16.2 Botagenesis Mutagenesis Disorder 16.1 How Supplied 16.2 Botagenesis Mutagenesis Disorder 16.1 How Supplied 17.2 Homos Disorder 18.2 Botagenesis Mutagenesis Disorder 19.3 Botagenesis Disorder 19.4 Depensive Disorde
	16.2 Storage and Handling 17 PATIENT COUNSELING INFORMATION
	* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal throughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressar use in patients aged 65 and older (see Warnings and Precautions (5.1)]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and Sympyax. Adult — Administer fluoxetine in combination with oral olanzapine once daily in the evening, without regard to meals, generally beginning with 5 mg of oral olanzapine and 20 mg of fluoxetine. Make dosage adjustments, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 mg to 50 mg and oral olanzapine 5 mg to 12.5 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 mg to 12 mg and fluoxetine 15 mg to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies. Periodically re-examine the need for continued pharmacotherapy. *Children and adolescents* (10-17 years of age) — Administer olanzapine and fluoxetine combination once daily in the evening,

uoxetine base equivalen

4 CONTRAINDICATIONS When using fluoxetine capsules and olanzapine in combination, also refer to the Contraindications section of the package sert for Symbyax.

1.25"H x 1.25"W

.625"

A1. Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine is contraindicated because of an increased risk of serotonin syndrome. The use of fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated *[see Dosage and Administration (2.9) and Warnings and*

Precautions (5.2)] Starting fluoxetine in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration (2.10) and Warnings and

itions (5.2)]. 4.2 Other Contraindications

The use of fluoxetine is contraindicated with the following:

Pimozide [see Warnings and Precautions (5.11) and Drug Interactions (7.7, 7.8)] Thioridazine [see Warnings and Precautions (5.11) and Drug Interactions (7.7, 7.8)]

Pimozide and thioridazine prolong the QT interval. Fluoxetine can increase the levels of pimozide and thioridazine through

tine can also prolong the QT interval. **5 WARNINGS AND PRECAUTIONS**

 \leftrightarrow

.625"

hen using fluoxetine and olanzapine in combination, also refer to the Warnings and Precautions section of the package insert

5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults

Patients with Major Depressive Disorder (MDD), both adult and pediatric, may experience worsening of their depression and/ or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicidal. There has and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicidal been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with Major Depressive Disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to clacebe in a dutts bayed for a 24 there was a reduction with antidepressants do and the adults bayed for a dutts bayed fo placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and olde placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. The pooled analyses of placebo-controlled trials in children and adolescents with MDD, Obsessive Compulsive Disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients trated) are provided in Table 2. ated) are provided in Table 2 Table 2: Suicidality per 1,000 Patients Treated

Age Range	e Drug-Placebo Difference in Number of Cases of Suicidalit per 1,000 Patients Treated		
	Increases Compared to Placebo		
< 18	14 additional cases		
18-24	5 additional cases		
	Decreases Compared to Placebo		
25-64	1 fewer case		
> 65	6 fewer cases		

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the

for Symbyax. 5.17 Sexual Dysfunction Use of SSRs, including fluoxetine, may cause symptoms of sexual dysfunction [see Adverse Reactions (6.1)]. In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgam. It is important for prescribers to inquire about sexual function prior to initiation of fluoxetine and to inquire specifically about changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment. 6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling:

recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, initiality, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for Major Depressive Disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precents to the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

worsening depression or suicidality, especially if these symptoms are severe, aurupt in onset, or work not part of the presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms *(see Warnings and Precautions (5.15))*. Families and caregivers of patients being treated with certain symptoms *(see Warnings and Precautions (5.15))*. Families and caregivers of patients being treated with antidepressants for Major Depressive Disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of suicidality, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for fluoxetine should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose. It should be noted that fluoxetine is approved in the pediatric population for Major Depressive Disorder and Obsessive Compulsive Disorder; and fluoxetine in combination with olanzapine for the acute treatment of depressive episodes associated with Bipolar I Disorder.

Revised: 3/2024

Null hiplotal District. 5.2 Sertotion Syndrome Selective serotonin reuptake inhibitors (SSRIs), including Fluoxetine, can precipitate serotonery of drugs (including triptans, tricyclic antidepressants, fentany), lithium, tramadol, trytophan, meperidine, methadone, buspirone, amphetamines, and SL John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs (see Contraindications (4), Drug Interactions (7.1)]. Serotonin syndrome can also occur when these drugs are used alone.

Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

symptoms (e.g., nausea, vomiting, diarrhea). The concomitant use of fluoxetine with MAOIs is contraindicated. In addition, do not initiate fluoxetine in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking fluoxetine, discontinue fluoxetine before initiating treatment with the MAOI *[see Contraindications (4) and Drug Interactions (7.1)]*. Monitor all patients taking fluoxetine for the emergence of serotonin syndrome. Discontinue treatment with fluoxetine and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of fluoxetine with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. **5.3 Alleroid Reactions and Rash**

5.3 Allergic Reactions and Rash In US fluoxetine clinical trials, 7% of 10,782 patients developed various types of rashes and/or urticaria. Among the cases of rash and/or urticaria reported in premarketing clinical trials, almost a third were withdrawn from treatment because of the rash and/or systemic signs or symptoms associated with the rash. Clinical findings reported in association with rash include fever, leukocytosis, arthralgias, edema, carpal tunnel syndrome, respiratory distress, lymphadenopathy, proteinuria, and mild transaminase elevation. Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. In premarketing clinical trials, 2 patients are known to have developed a serious cutaneous systemic illness. In neither patient was there an unequivocal diagnosis, but one was considered to have a leukocytoclastic vasculitis, and the other, a severe

desquamating syndrome that was considered variously to be a vasculitis or erythema multiforme. Other patients have had ystemic syndromes suggestive of serum sickness. Since the introduction of fluoxetine, systemic reactions, possibly related to vasculitis and including lupus-like syndrome, have leveloped in patients with rash. Although these reactions are rare, they may be serious, involving the lung, kidney, or liver.

eath has been reported to occur in association with these systemic reactions. Anaphylactoid reactions, including bronchospasm, angioedema, laryngospasm, and urticaria alone and in combination, have

Pulmonary reactions, including inflammatory processes of varying histopathology and/or fibrosis, have been reported rarely.

These reactions have occurred with dyspnea as the only preceding symptom. Whether these systemic reactions and rash have a common underlying cause or are due to different etiologies or pathogenic

predispose to QT prolongation and ventricular arrhythmia. Such conditions include concomitant use of drugs that prolong the QT interval; hypokalemia or hypomagnesemia; recent myocardial infarction, uncompensated heart failure, bradyarrhythmias, and other significant arrhythmias, and conditions that predispose to increased fluxetine exposure (overdose, hepatic impairment, use of CYP2D6 inhibitors, CYP2D6 (spee Contraindications (4.2), Adverse Reactions (6.2), Drug Interactions (7.7, 7.8), Overdosage (10), and Clinical Pharmacology (12.3)].
 Pimozide and thioridazine are contraindicated for use with fluxetine. Avoid the concomitant use of drugs known to prolong the QT interval. These include specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol, ; specific antibiotics (e.g., erythromycin, gatifoxacin, moxifoxacin, sparloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofartnire, mefloquine, dolasetron mesylate, probucol or tacrolimus) *[see Drug Interactions (7.7, 7.8) and Clinical Pharmacology (12.3)].* Consider ECG assessment and periodic ECG monitoring if initiating treatment with fluxetine in patients with risk factors for OT prolongation and ventricular arrhythmia.
 Sta Use in Patients with Concomitant Illness
 Clinical experience with fluxetine in patients with could affect metabolism or hemodynamic responses.
 Cardiovascular — Fluxetine has not been evaluated or used to any appreciable extent in patients with a recent history of myocaridia infarction or unstable heats disease. Fluxetine and progrego sproximately 3 beats/min.
 Gycemic Control — In patients with diabetes, fluxetine may alter glycemic control. Hypoglycemia has occurred fluxetine in dubiet-blind trials were retrospectively evaluated; no conduction abnormalities tha

of potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with fluoxetine and norfluoxetine following the discontinuation of fluoxetine [see Clinical Pharmacology (12.3)]. 5.15 Discontinuation Adverse Reactions During marketing of fluoxetine, SNRIs, and SSRIs, there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. While these reactions are generally self-limiting, there have been reports of serious discontinuation of the symptoms. Patients should be monitored for these symptoms when discontinuing the retrevolts of serious discontinuation and a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the healthcare provider may continue decreasing the dose but at a more gradual rate. Plasma fluoxetine and onfluoxetine concentration decrease gradually at the conclusion of therapy which may minimize the risk of discontinuation symptoms with this drug. 5.16 Fluoxetine and olanzapine in Combination When using fluoxetine and olanzapine in combination also refer to the Warnings and Precautions section of the package insert for Symbyax.

Following adverse reactions are discussed in more detail in other sections of the labeling: Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults [see Boxed Warning and Warnings and Precautions

Allergic Reactions and Rash [see Warnings and Precautions (5.3)] Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypomania [see Warnings and Precautions (5.4)] Seizures [See Warnings and Precautions (5.5)]

Antibuty and instrumings and Precautions (5, 10)
 (1) Torolongation (see Warnings and Precautions (5, 11)]
 Potential for Cognitive and Motor Impairment (see Warnings and Precautions (5, 13)]
 Discontinuation Adverse Reactions (see Warnings and Precautions (5, 15)]
 Sexual Dysfunction (see Warnings and Precautions (5, 17)]
When using fluoxetine and olanzapine in combination, also refer to the Adverse Reactions section of the package insert for
Surphysical Section 2014

6.7 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in creatica

of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice. Multiple doses of fluoxetine have been administered to 10,782 patients with various diagnoses in US clinical trials. In addition, there have been 425 patients administered fluoxetine in panic clinical trials. The stated frequencies represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment-emergent adverse reaction controlled clinical trials (schulding data from extensions of trials) — Table 3 enumerates the most common treatment-emergent adverse reactions associated with the use of fluoxetine of Major Depressive Disorder, OCD, bullima, and Panic Disorder placebo within at least 1 of the indications) for the treatment of Major Depressive Disorder, OCD, and bullima in US controlled clinical trials and Panic Disorder in US plus non-US controlled trials and Panic Disorder placebo within at least 1 of the indications) for the treatment of Major Depressive Disorder, OCD, and bullima in US controlled clinical trials and Panic Disorder placebo, and the adverse reactions associated with the use of fluoxetine (incidence of at least 5% for fluoxetine and at least twice that for placebo within at least 1 of the indications) for the treatment of Major Depressive Disorder, OCD, and bullima in US controlled clinical trials and Panic Disorder fluoxetine and with incidence greater than placebo who participated in US Major Depressive Disorder, OLD, and bullima controlled clinical trials and Panic Disorder, OLD, and bullima controlled clinical trials and US plus non-US partic Disorder placebo who participated in US Major Depressive Disorder, OCD, and bullima controlled clinical trials and US plus non-US panic Disorder placebo-Controlled clinical trials. Table 4 provides combined data for the pool of studies that are provide separately by indication in Table 3. Table 3: Most Com

Percentage of Patients Reporting Even

r Depressive

9

3

11

OCD

 $\begin{array}{|c|c|c|c|c|c|c|c|} \hline Fluoxetine & Placebo \\ (N = 1,728) & (N = 975) \end{array} \begin{array}{|c|c|c|c|c|c|c|c|} Fluoxetine & Placebo \\ (N = 266) & (N = 89) \end{array} \begin{array}{|c|c|c|c|c|c|c|} Fluoxetine & Placebo \\ (N = 450) & (N = 267) \end{array}$

10 7

26 13

5 15 11 21 9

 ...
 13
 8
 6

 2
 17
 10
 8
 4

 7
 12
 3
 0
 1

8

29

3

11

10 6

(N = 342)

5

(N = 425)

5

12

4

4

6

9

- for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1)].
- tine is not approved for use in children less than 7 years of age [see Warnings and Precautions (5.1)

and Use in Specific Populations (8.4)]. When using fluoxetine and olanzapine in combination, also refer to Boxed Warning section of the package insert for Symboax.

1 INDICATIONS AND LISAGE

22

Ô

- VolcA flows AND USAGE oxetine is indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder *[see Clinical Studies (14.1)].* Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD)
- [see Clinical Studies (14.2)].
 Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia
- Nervosa [see Clinical Studies (14.3)]. Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4)].
- etine and Olanzapine in Combination is indicated for the treatment of:

Acute treatment of depressive episodes associated with Bipolar 1 Disorder. Treatment resistant depressive episodes associated with Bipolar 1 Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode).

Fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression

When using fluoxetine and olanzapine in combination, also refer to the Clinical Studies section of the package insert for

2 DOSAGE AND ADMINISTRATION

2.1 Maior Depressive Disorder

Initial Treatment Adult — Initiate fluoxetine 20 mg/day orally in the morning. Consider a dose increase after several weeks if insufficient clinical Improvement is observed. Administer does above 20 mg/day once daily in the morning or twice daily (i.e., morning and noon). The maximum fluoxetine dose should not exceed 80 mg/day. In controlled trials used to support the efficacy of fluoxetine, patients were administered morning doses ranging from the data of the base of the support of the efficacy of fluoxetine.

20 to 80 mg/day. Studies comparing fluoxetine 20 mg/day, 40 mg/day, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in Major Depressive Disorder in most cases *[see Clinical Studies*

iatric (children and adolescents) — Initiate Fluoxetine 10 mg/day or 20 mg/day. After 1 week at 10 mg/day, increase the dose to 20 mg/day. However, due to higher plasma levels in lower weight children, the starting and target dose in this group may be 10 mg/day. Consider a dose increase to 20 mg/day after several weeks if insufficient clinical improvement is observed. In the short-term (8 to 9 week) controlled clinical triats of fluoxetine supporting its effectiveness in the treatment of Major Depressive Disorder, patients were administered fluoxetine doses of 10 mg/day to 20 mg/day [see Clinical Studies (14.1)]. All patients — As with other drugs effective in the treatment of Major Depressive Disorder, the full effect may be delayed until

weeks of treatment or longer.
 Periodically reassess to determine the need for maintenance treatment.
 Switching Patients to a Tricyclic Antidepressant (TCA) — Dosage of a TCA may need to be reduced, and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued [see Warnings and Precautions (5.2) and Drug Interactions (7.7)].
 2.2 Obsessive Compulsive Disorder Initial Treatment

Initial Treatment Adult— Initiate fluoxetine 20 mg/day, orally in the morning. Consider a dose increase after several weeks if insufficient clinical Adult — Initiate notes the 20 ing/day, or any in the informing. Consider a dose inclease after several weeks inisinitetri clinical improvement is observed. The full therapeutic effect may be delayed until 5 weeks of treatment or longer. Administer doses above 20 mg/day once daily in the morning or twice daily (i.e., morning and noon). A dose range of 20 mg/day to 60 mg/day is recommended; however, doses of up to 80 mg/day have been well tolerated in open studies of OCD. The maximum fluxestine dose should not exceed 80 mg/day. In the controlled clinical trials of fluxestine supporting its effectiveness in the treatment of OCD, patients were administered fixed daily doses of 20 mg, 40 mg, or 60 mg of fluxestine or placebo [see Clinical Studies (14.2)]. In one of these studies, no

dose-response relationship for effectiveness was demonstrated. Pediatric (children and adolescents) — In adolescents and higher weight children, initiate treatment with a dose of 10 mg/day. After 2 weeks, increase the dose to 20 mg/day Consider additional dose increases after several more weeks if insufficient clinical improvement is observed. A dose range of 20 mg/day to 30 mg/day is recommended. In lower weight children, initiate treatment with a dose of 10 mg/day. Consider additional dose increases after several more weeks if insufficient clinical improvement is observed. A dose range of 20 mg/day to 30 mg/day to 30 mg/day is recommended. Experience with daily doses greater than 20 mg is very minimal, and there is no experience with doses greater than 60 mg. In the controlled clinical trial of fluxertine supporting its effectiveness in the treatment of OCD, patients were administered fluxetine doses in the range of 10 mg/day to 60 mg/day [see Clinical Studies (14.2)]. Periodically reasses to determine the need for treatment. 2.3 Builma Nervosa

2.3 Sultima Nervosa Initial Treatment — Administer fluoxetine 60 mg/day in the morning. For some patients it may be advisable to titrate up to this Initial realized — Automote to use the operating of the molecular for some patients in may be advisable to use up to this target does over several days. Fluoxetine does above 60 mg/day have not been systematically studied in patients with bullimia. In the controlled clinical trials of fluoxetine does above 60 mg rob on go rob been systematically studied in patients with bullimia. In the controlled clinical trials of fluoxetine does of 20 mg or 60 mg, or placebo [see *Clinical Studies* (14.3)]. Only the 60 mg does was statistically significantly superior to placebo in reducing the frequency of binge-eating and vomiting. Periodically reassess to determine the need for maintenance treatment.

2.4 Panic Disorder

nitial Treatment — Initiate treatment with fluoxetine 10 mg/day. After one week, increase the dose to 20 mg/day. Consider a dose increase after several weeks if no clinical improvement is observed. Fluoxetine doses above 60 mg/day have not been systematically evaluated in patients with Panic Disorder. In the controlled clinical triats of fluoxetine supporting its effectiveness in the treatment of Panic Disorder, patients were administered fluoxetine doses in the range of 10 mg/day to 60 mg/day [see Clinical Studies (14.4]]. The most frequently administered dose in the 2 flexible-dose clinical trials was 20 mg/day

ess to determine the need for continued treatment. dicallv rea

2.5 Fluoxetine and Olanzapine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using fluoxetine and olanzapine in combination, also refer to the Clinical Studies section of the package insert for

Children and adolescents (10-17 years of age) — Administer olanzapine and fluoxetine combination once daily in the evening, generally beginning with 2.5 mg of olanzapine and 20 mg of fluoxetine. Make dosage adjustments, if indicated, according to efficacy and tolerability. Safety of co-administration of doses above 12 mg of olanzapine with 50 mg of fluoxetine has not been evaluated in pediatric clinical studies. Periodically re-examine the need for continued pharmacotherapy. Safety and efficacy of fluoxetine in combination with olanzapine was determined in clinical traits supporting approval of Symbyax (fixed-dose combination of olanzapine and fluoxetine). Symbyax is dosed between 3 mg/25 mg (olanzapine/fluoxetine) per day and 12 mg/50 mg (olanzapine/fluoxetine) per day. The following table demonstrates the appropriate individual component doses of fluoxetine and olanzapine versus Symbyax. Adjust dosage, if indicated, with the individual components according to efficace y and forerability. fficacy and tolera

Table 1: Approximate Dose Correspondence Between Symbyax¹ and the Combination of Fluoxetine and Olanzapine

For Symbyax (mg/day)	Use in Combination	
	Olanzapine (mg/day)	Fluoxetine (mg/day)
3 mg olanzapine/25 mg fluoxetine	2.5	20
6 mg olanzapine/25 mg fluoxetine	5	20
12 mg olanzapine/25 mg fluoxetine	10+2.5	20
6 mg olanzapine/50 mg fluoxetine	5	40+10
12 mg olanzapine/50 mg fluoxetine	10+2.5	40+10

¹Symbyax (olanzanine/fluoxetine HCL) is a fixed-dose combination of fluoxetine and olanzanine

Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 2.6 Fluoxetine and Olanzapine in Combination: Treatment Resistant Depression When using Fluoxetine and olanzapine in combination, also refer to the Clinical Studies section of the package insert for

Symbyax. Administer fluoxetine in combination with oral olanzapine once daily in the evening, without regard to meals, generally beginning with 5 mg of oral olanzapine and 20 mg of fluoxetine. Adjust dosage, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 mg to 50 mg and oral olanzapine 5 mg to 20 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 mg to 18 mg and fluoxetine 20 Safety and efficacy of fluoxetine in combination with olanzapine was determined in clinical trials supporting approval of Symbyax (fixed dose combination of olanzapine and fluoxetine). Symbyax is dosed between 3 mg/25 mg (olanzapine/fluoxetine) per day and 12 mg/50 mg (olanzapine/fluoxetine) per day. Table 1 demonstrates the appropriate individual component doses of fluoxetine and olanzapine versus Symbyax. Adjust dosage, if indicated, with the individual components according to efficacy and tolerability.

and tolerability. Periodically re-examine the need for continued pharmacotherapy. Safety of coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies. Fluoxetine monotherapy is not indicated for the treatment of treatment resistant depression (Major Depressive Disorder in patients who do not respond to 2 antidepressants of adequate dose and duration in the current episode). 2.7 Dosing in Specific Populations Corrigina - Consider a leure or lease frequent depress for the alderly fong lease in Specific Deputedman (8 EU

nsider a lower or less frequent dosage for the elderly [see Use in Specific Populations (8.5)]. nent — As with many other medications use a lower of the state.

Consider a lower or less frequent dosage for the elderly [see Use in Specific Populations (8.5)].
 Hepatic Impairment — As with many other medications, use a lower or less frequent dosage in patients with hepatic impairment [see Clinical Pharmacology (12.4) and Use in Specific Populations (8.6)].
 Concomitant Illness — Patients with concurrent disease or on multiple concomitant medications may require dosage adjustments [see Clinical Pharmacology (12.4) and Warnings and Precautions (5.12)].
 Fluoxetine and Olanzapine in Combination — Use a starting dose of oral olanzapine 2.5 mg to 5 mg with fluoxetine 20 mg for patients with a predisposition to hypotensive reactions, patients with hepatic impairment, or patients who exhibit a combination of factors that may slow the metabolism of olanzapine or fluoxetine in combination. Further slowly and adjust dosage as needed in patients who exhibit a combination of factors that may slow metabolism. Fluoxetine and olanzapine in combination factors that during and Precautions (5.16).
 28 Discontinuation of Treatment 29 Symptoms associated with discontinuation of fluorette of the sectors (7.7)].

trinuation of Treatment associated with discontinuation of fluoxetine, SNRIs, and SSRIs, have been reported [see Warnings and Precautions]

At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric Disorders At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of herapy with fluxetine. Conversely, at least 5 weeks should be allowed after stopping fluxetine before starting an MAOI intended to treat psychiatric disorders [see Contraindications (4.1)].

The radius for days and the provided state of the set o

3 DOSAGE FORMS AND STRENGTHS

ISAGE FORMS AND STRENGTHS Fluoxetine capsules, USP 10 mg** are white to off white powder filled in size "4" hard gelatin capsules with opaque light blue colored cap and opaque light orange colored body imprinted "SG" on cap and "113" on body with black ink. Fluoxetine capsules, USP 20 mg** are white to off white powder filled in size "2" hard gelatin capsules with opaque ligh blue colored cap and opaque light green colored body imprinted "SG" on cap and "114" on body with black ink. Fluoxetine capsules, USP 40 mg** are white to off white powder filled in size "0" hard gelatin capsules with opaque ligh blue colored cap and opaque light green colored body imprinted "SG" on cap and "114" on body with black ink.

nague light

- opaque light

processes is not known. Furthermore, a specific underlying immunologic basis for these reactions has not been identified. Upon the appearance of rash or of other possibly allergic phenomena for which an alternative etiology cannot be identified, etine should be disco

5.4 Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypo

A major depressive episode may be the initial presentation of Bipolar Disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for Bipolar Disorder. Whether any of the symptoms described for clinical worsening and suicide risk represent such a conversion is unknown. However, prior to initiating freatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for Bipolar Disorder; such screening should include a detailed psychiatric history, including a family history of suicide, Bipolar Disorder, and depression. It should Should include a deviate psychiatric history, including a family mistory of succee, sipolar Disorder, and depression. It should be noted that fluoxetine and olanzapine in combination is approved for the acute treatment of depression. It should with Bipolar I Disorder [see Warnings and Precautions section of the package insert for Symbyay, Fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. In US placebo-controlled clinical trials for Major Depressive Disorder, mania/hypomania was reported in 0.1% of patients treated with fluoxetine and 0.1% of patients treated with placebo. Activation of mania/hypomania has also been reported in a small proportion of patients with Major Affective Disorder treated with other marketed drugs effective in the treatment of Major

Depressive Disorder [see Use in Specific Populations (8.4)]. In US placebo-controlled clinical trials for OCD, mania/hypomania was reported in 0.8% of patients treated with fluoxetine and no patients treated with placebo. No patients reported mania/hypomania in US placebo-controlled clinical trials for bulimia. In US fluoxetine clinical trials, 0.7% of 10,782 patients reported mania/hypomania [see Use in Specific Populations (8.4)]. 5.5 Seizures

In US placebo-controlled clinical trials for Major Depressive Disorder, conv In Corplace of the second of t

5.6 Altered Appetite and Weight

Significant weight loss, especially in underweight depressed or bulimic patients, may be an undesirable result of treatment with fluoxetine.

In US placebo-controlled clinical trials for Major Depressive Disorder, 11% of patients treated with fluoxetine and 2% of In US placebo-controlled clinical traits for major Depressive Disorder, 11% of platents treated with nuoxetine and 2% of patients treated with placebo reported anorxia (decreased appetite). Weight loss was reported in 1.4% of patients treated with fluoxetine and in 0.5% of patients treated with placebo. However, only rarely have patients discontinued treatment with fluoxetine because of anorexia or weight loss (*see Use in Specific Populations (8.4)*). In US placebo-controlled clinical trials for 0CD, 17% of patients treated with fluoxetine and 10% of patients treated with placebo reported anorexia (decreased appetite). One patient discontinued treatment with fluoxetine because of anorexia (*see Use in Cherotic Develotions (0.4*).

pecific Populations (8.4)].

In US placebo-controlled clinical trials for Bulimia Nervosa, 8% of patients treated with fluoxetine 60 mg and 4% of pa treated with placebo reported anorexia (decreased appetite). Patients treated with fluoxetine 60 mg on average lost 0.45 kg compared with a gain of 0.16 kg by patients treated with placebo in the 16-week double-blind trial. Weight change should be monitored during therapy. 5.7 Increased Risk of Bleeding

SNRIs and SSRIs, including fluoxetine, may increase the risk of bleeding reactions. Concomitant use of aspirin, nonst SMHs and SSHIs, including fluoxetine, may increase the risk of bleeding reactions. Concomitant use of aspirin, nonsteroidal studies andi-inflammatory drugs, warfarin, and other anti-coegulatins may add to this risk. Case reports and epidemiological studies (case control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartium hemorrhage [see Use in Specific Populations (8.1)]. Bleeding reactions related to SMRIs and SSRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of fluoxetine and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation [see Drug Interactions (7.4)].

5.8 Angle-Closure Glaucoma Angle-Closure Glaucoma — The pupillary dilation that occurs following use of many antidepressant drugs including fluoxetine may trigger an angle-closure attack in a patient with anatomically narrow angles who does not have a patent indectomy.

emia has been reported during treatment with SNRIs and SSRIs, including fluoxetine. In many cases, this hyponatremi appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodiun ower than 110 mmol/L have been reported and appeared to be reversible when fluoxetine was discontinued. Elderly patients Now of the provided and the provided and appeared to be reversible within 100xettine Was discontinued. Elderly patients may be at greater risk of developing hyponatremia with SNRs and SSRs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk (see Use in Specific Populations (8.5)). Discontinuation of fluoxetine should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to fails. More severe and/or acute cases have been associated with hallucination, syncope, poirume come, prepiratory arget and death.

seizure, coma, respiratory arrest, and death. 5.10 Anxiety and Insomnia

controlled clinical trials for Major Depressive Disorder, 12% to 16% of patients treated with fluoxetine and 7% to n US place

Why of patients treated with placebo reported anxiety, nervousness, or insomnia. In US placebo-controlled clinical trials for OCD, insomnia was reported in 28% of patients treated with fluoxetine and in 22% of patients treated with placebo. Anxiety was reported in 14% of patients treated with fluoxetine and in 7% of patients treated ith placebo.

ontrolled clinical trials for Bulimia Nervosa, insomnia was reported in 33% of patients treated with flu In US placebo-c 60 mg, and 13% of patients treated with placebo. Anxiety and nervousness were reported, respectively, in 15% and 11% of patients treated with fluoxetine 60 mg and in 9% and 5% of patients treated with placebo.

Among the most common adverse reactions associated with discontinuation (incidence at least twice that for placebo and at least 1% for fluoxetine in clinical trials collecting only a primary reaction associated with discontinuation) in US placebo-controlled fluoxetine clinical trials were anxiety (2% in OCD), insomnia (1% in combined indications and 2% in bulimia), and ness (1% in Major Depressive Disorder) *[see Table 5]*

5.11 QT Prolongation Post-marketing cases of QT interval prolongation and ventricular arrhythmia including Torsades de Pointes have been reported in patients treated with fluoxetine. Fluoxetine should be used with caution in patients with congenital long QT syndrome; a previous history of QT prolongation; a family history of long QT syndrome or sudden cardiac death; and other conditions that

IIISUIIIIId	10	9	20	22	33	10	10	1
Anxiety	12	7	14	7	15	9	6	2
Nervousness	14	9	14	15	11	5	8	6
Somnolence	13	6	17	7	13	5	5	2
Tremor	10	3	9	1	13	1	3	1
Libido decreased	3		11	2	5	1	1	2
Abnormal dreams	1	1	5	2	5	3	1	1
Respiratory System								
Pharyngitis	3	3	11	9	10	5	3	3
Sinusitis	1	4	5	2	6	4	2	3
Yawn			7		11		1	
Skin and Appendages								
Sweating	8	3	7		8	3	2	2
Rash	4	3	6	3	4	4	2	2
Urogenital System								
Impotence ³	2				7		1	
Abnormal ejaculation ³			7		7		2	1

(5.1)]

Body System

Adverse Reaction

Body as a Whole

Cardiovascular Sys

Digestive System

Nausea

Diarrhea

Dry mouth

Dyspepsia

Nervous System

Asthenia Flu syndrom

tonin Syndrome [see Warnings and Precautions (5.2)]

Seizures (see warnings and Precautions (5.5)] Altered Appetite and Weight (see Warnings and Precautions (5.6)] Increased Risk of Bleeding (see Warnings and Precautions (5.7)] Angle-Closure Glaucoma (see Warnings and Precautions (5.8)] Hyponatremia (see Warnings and Precautions (5.10)] Anxiety and Insomnia (see Warnings and Precautions (5.10)] Of Declared tion for Mergina and Decentring (5.10)]

Incidence less than 1%. Includes US data for Major Depressive Disorder, OCD, Bulimia, and Panic Disorder clinical trials, plus non-US data for Panic Disorder the latent defined. Disorder clinical trials

³ Denominator used was for males only (N = 690 fluoxetine Major Depressive Disorder; N = 410 placebo Major Depressive Disorder; N = 116 fluoxetine OCD; N = 43 placebo OCD; N = 14 fluoxetine bulimia; N = 1 placebo bulimia; N = 162 fluoxetine panic; N = 121 placebo panic).

$_{\rm panic,\,n}=$ 1/2 piaceoo panic). Table 4: Treatment-Emergent Adverse Reactions: Incidence in Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Placebo-Controlled Clinical Trials'^2

	Percentage of Patients Reporting Event			
	Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Combine			
Body System/ Adverse Reaction	Fluoxetine (N = 2,869)	Placebo (N = 1,673)		
Body as a Whole				
Headache	21	19		
Asthenia	11	6		
Flu syndrome	5	4		
Fever	2	1		
Cardiovascular System				
Vasodilatation	2	1		
Digestive System				
Nausea	22	9		
Diarrhea	11	7		
Anorexia	10	3		
Dry mouth	9	6		
Dyspepsia	8	4		
Constipation	5	4		
Flatulence	3	2		
Vomiting	3	2		
Metabolic and Nutritional Disorders				
Weight loss	2	1		
Nervous System				
Insomnia	19	10		
Nervousness	13	8		
Anxiety	12	6		
Somnolence	12	5		
Dizziness	9	6		
Tremor	9	2		
Libido decreased	4	1		
Thinking abnormal	2	1		
Respiratory System				
Yawn	3			

9.125"

17.0" W

 \leftrightarrow

.625"

Bottles of 1000 NDC 77771-114-01

Fluoxetine base equivalent

eek medical care immed

Angle-Closure Glaucom

OT Prol

Allergic Reactions and Rash

endpoint, ranged from 1 to 2 episodes per week for binge-eating and 2 to 4 episodes per week for vomiting. The size of the effect was related to baseline frequency, with greater reductions seen in patients with higher baseline frequencies. Although some patients achieved freedom from binge-eating and purging. In a longer-term trial, 150 patients meeting DSM-IV criteria for Bulimia Nervosa, purging subtype, who had responded during a single-blind, 8-week acute treatment phase with fluoxetine 60 mg/day, were randomized to continuation of fluoxetine 60 mg/day or placebo, for up to 52 weeks of observation for relapse. Response during the single-blind phase was defined as a persistent return to baseline vomiting frequency or phaethcare provider judgment that the patient had relapse. Patients receiving continued fluoxetine 60 mg/day experienced a significantly longer time to relapse news of fluoxetine in the treatment of Panic Disorder was demonstrated in 2 double-blind, randomized, placebo-controlled, multicenter studies of adult outpatients who had a primary diagnosis of Panic Disorder (DSM-IV), with or without agoraphobia.

Controlled, induced to bath department in the first week parally begins in the basis of clinical response and tolerability. Study 1 (N = 180 randomized) was a 12-week flexible-dose study. Fluoxetine was initiated at 10 mg/day for the first week, after which patients were dosed in the range of 20 mg/day to 60 mg/day on the basis of clinical response and tolerability. A statistically significantly greater percentage of fluoxetine-treated patients were free from panic attacks at endpoint than placebo-treated patients, 42% versus 28%, respectively. Study 2 (N = 214 randomized) was a 12-week flexible-dose study. Fluoxetine was initiated at 10 mg/day for the first week, after which patients were dosed in a range of 20 mg/day to 60 mg/day on the basis of clinical response and tolerability. A statistically significantly greater percentage of fluoxetine-treated patients were free from panic attacks at endpoint than placebo-treated patients, 62% versus 44%, respectively. **16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied**

16 HOW SUPPLED/STORAGE AND HANDLING 16.1 How Supplied Fluoxetine Capsules, USP 10 mg** are white to off white powder filled in size "4" hard gelatin capsules with opaque light blue colored cap and opaque light orange colored body imprinted "SG" on cap and "113" on body with black ink. Bottles of 1000 NDC 77771-113-0

Fluoxetine Capsules USP, 20 mg** are white to off white powder filled in size "2" hard gelatin capsules with opaque light blue colored cap and opaque light green colored body imprinted "SG" on cap and "114" on body with black ink. Bottles of 100 NDC 7771-114-01

 Fluoxetine Capsules USP, 40 mg** are white to off white powder filled in size "0" hard gelatin capsules with opaque light blue colored cap and opaque white colored body imprinted "SG" on cap and "115" on body with black ink.

 Bottles of 100
 NDC 77771-115-01

 Bottles of 500
 NDC 77771-115-05

Protocome base equivalent: **16.2. Storage and Handling** Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. **17 PATIENT COUNSELING INFORMATION** Advise the patient to read the FDA-approved patient labeling (Medication Guide). Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking fluoxetine as monotherapy or in combination with oharzapine. When using fluoxettine and olanzapine in combination, also refer to the Patient Counseling Information section of the package insert for Symbyax.

General information Healthcare providers should instruct their patients to read the Medication Guide before starting therapy with fluoxetine and to reread it each time the prescription is renewed. Healthcare providers should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with fluoxetine and should counsel them in its appropriate use. Healthcare providers should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they grave base.

nave. ants should be advised of the following issues and asked to alert their healthcare provider if these occur while taking

fluoxetine. When using fluoxetine and olanzapine in combination, also refer to the Medication Guide for Symbyax. Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Aduts Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication [see Box Warning and Warnings and *Precautions (5.1)*].

Patients should be advised of the signs and symptoms associated with serotonin syndrome that may include mental status

changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular changes (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be cautioned to

experience these symptoms. Increased Risk of Bleeding Patients should be cautioned about the concomitant use of fluoxetine and NSAIDs, aspirin, warfarin, or other drugs that affect

reactions anotation concentration to concentration to a concentration of motoration and monorady, applicing with an interfere consignation and the constituent use of psychologic drugs that interfere with servolumi reuptake and these agents have been associated with an increased risk of bleeding *(see Warnings and Precautions (5,7) and Drug Interactions (7,4)*). Patients should be advised to call their healthcare provider if they experience any increased or unusual bruising or bleeding with teaking

autoriso should our data user and the second second

Patients should be advised that hyponatremia has been reported as a result of treatment with SNRIs and SSRIs, including

functions and use advice that information as occir house as a section of the advice in the advice intervention of the advice inte

Patients should be advised that QT interval prolongation and ventricular arrhythmia including Torsades de Pointes have been

rations anotate during a unique and a promisation and symptoms of ventrotate anny uniter include task, site on inter nee beer reported in patients treated with fluoxeline. Signs and symptoms of ventrotate arrhythmia include fast, site, so, or integralar hear rate, dyspnea, syncope, or dizziness, which may indicate serious cardiac arrhythmia [see Warnings and Precautions (5.11)]. Potential for Cognitive and Motor impairment

Fluoxetine may impair judgment, thinking, or motor skills. Patients should be advised to avoid driving a car or operating

azardous machinery until they are reasonably certain that their performance is not affected [see Warnings and Precaution

Patients should be advised to inform their healthcare provider if they are taking, or plan to take, any prescription medication, including Symbyax, Sarafem, or over-the-counter drugs, including herbal supplements or alcohol. Patients should also be advised to inform their healthcare providers if they plan to discontinue any medications they are taking while on fluoxetine.

Patients should be advised to take fluoxetine exactly as prescribed, and to continue taking fluoxetine as prescribed even after

their symptoms improve. Patients should be advised that they should not alter their dosing regimen, or stop taking fluoxetine without consulting their healthcare provider [see Warnings and Precautions (5.15)]. Patients should be advised to consult with their healthcare provider if their symptoms do not improve with fluoxetine.

Advise patients that use of fluoxetine may cause symptoms of sexual dysfunction in both male and female patients. Inform

patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider [see Warnings and Precautions (5.17)].

rophylactic procedure (e.g., iridectomy), if they are susceptible [See Warnings and Precautions (5.8)].

nts should be advised that taking fluoxetine can cause mild pupillary dilation, which in susceptible individuals, can lead to

nts should be advised to notify their healthcare provider if they develop a rash or hives *[see Warnings and Precautions*] (5.3)). Patients should also be advised of the signs and symptoms associated with a severe allergic reaction, including swelling of the face, eyes, or mouth, or have trouble breathing. Patients should be cautioned to seek medical care immediately if the

allo intractic a river for the set of the se

tely if they experience these symp

Width: 17.0" Length: 18.75' Fold: 1.25" x 1.25"

	Percentage of Patients Reporting Event			
	Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Combined			
Body System/ Adverse Reaction	Fluoxetine (N = 2,869)	Placebo (N = 1,673)		
Skin and Appendages				
Sweating	7	3		
Rash	4	3		
Pruritus	3	2		
Special Senses				
Abnormal vision	2	1		

¹ Incidence less than 1% ² Includes US data for Major Depressive Disorder, OCD, Bulimia, and Panic Disorder clinical trials, plus non-US data for Panic

Associated with discontinuation in Major Depressive Disorder, OCD, bulimia, and Panic Disorder placebo-controlled clinical trials (excluding data from extensions of trials) — Table 5 lists the adverse reactions associated with discontinuation of fluoxetine treatment (incidence at least twice that for placebo and at least 1% for fluoxetine in clinical trials collecting only a primary reaction associated with discontinuation) in Major Depressive Disorder, OCD, bulimia, and Panic Disorder clinical trials, non-US Panic Disorder clinical trials.

able 5: Most Common Adverse Reactions Associated with Discontinuation in Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Placebo-Controlled Clinical Trials

Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Combined (N = 1,533)	Major Depressive Disorder (N = 392)	OCD (N = 266)	Bulimia (N = 450)	Panic Disorder (N = 425)
Anxiety (1%)		Anxiety (2%)		Anxiety (2%)
			Insomnia (2%)	
	Nervousness (1%)			Nervousness (1%)
		Rash (1%)		

Includes US Major Depressive Disorder, OCD, Bulimia, and Panic Disorder clinical trials, plus non-US Panic Disorder clinical

Other adverse reactions in pediatric patients (children and adolescents) — Treatment-emergent adverse reactions were collected in 322 pediatric patients (180 fluoxetine-treated, 142 placebo-treated). The overall profile of adverse reactions was generally similar to that seem in adult studies, as shown in Tables 4 and 5. However, the following adverse reactions (excluding those which appear in the body or footnotes of Tables 4 and 5 and those for which the COSTART terms were uninformative or the second se misleading) were reported at an incidence of at least 2% for fluoxetine and greater than placebo; thirst, hyperkinesia, agitation,

Instanting were reported at an inclusive of at least 2% for houseful and greater than placeto, times, hyperkinesia, agration, personality disorder, epistakis, unitary frequency, and memorrhagia. The most common adverse reaction (incidence at least 1% for fluoxetine and greater than placebo) associated with discontinuation in 3 pediatric placebo-controlled trials (N = 418 randomized; 228 fluoxetine-treated; 190 placebo-treated) was mania/hypomania (1.3% for fluoxetine-treated, 0% for placebo-treated). In these clinical trials, only a primary reaction associated with discontinuation was collected.

associated with discontinuation was collected. Male and female sexual dysfunction with SSRIs — Although changes in sexual desire, sexual performance, and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that SSRIs can cause such untoward sexual experiences. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and healthcare providers may be reluctant to discuss them. Accordingly, estimates of the incidence and severity of untoward on the analthcare providers may be reluctant to discuss them. Accordingly, estimates of the incidence and severity of untoward on the analthcare providers may be reluctant to discuss them. Accordingly, estimates of the incidence and severity of untoward on the analthcare providers may be reluctant to discuss them. Accordingly, estimates of the individence and severity of untoward on the analthcare providers may be reluctant to discuss them. Accordingly, estimates of the individence and severity of untoward because and advectore the dividence of the providence and the advector of the incidence and because the severity of the incidence and the advector of the incidence advector of the advector of the incidence advector of the incidence advector of the advector of the advector of the advector of the incidence advector of the incidence advector of the advector o butain, nowever, in pair because patients and nearincare provides hidy be reluctant to uscuss memory activity, estimates of the incidence of untoward sexual experience and performance, cited in product labeling, are likely to underestimate their actual incidence. In patients enrolled in US Major Depressive Disorder, OCD, and bulimia placebo-controlled clinical trials, decreased libido was the only sexual size effect reported by at least 2% of patients taking fluoxetine (4% fluoxetine, 4% placebo). There have been spontaneous reports in women taking fluoxetine of orgasmic dysfunction, including anorgasmia.

There are no adequate and well-controlled studies examining sexual dysfunction with fluoxetine treatment. Symptoms of sexual dysfunction occasionally persist after discontinuation of fluoxetine treatment.

Priapism has been reported with all SSRIs.

While it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRIs, healthcare providers should routinely inquire about such possible side effects.

Other Reactions

25

Ô

Following is a list of treatment-emergent adverse reactions reported by patients treated with fluoxetine in clinical trials. This listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical mplications, or (5) which occurred at a rate equal to or less than placebo.

Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1,000 patients; rare reactions are those occurring in the state of the state o g in fewer than 1/1.000 patients.

- Frequent: chills; Infrequent: suicide attempt; Rare: acute abdominal syndrome, photosensitivity reaction lody as a Whole Cardiovascular System — Frequent: palpitation; Infrequent: arrhythmia, hypotension¹.

Digestive System — Infrequent: dysphagia; gastrilis; gastroenteritis; gastroenteritis; melean, stomach ulcer, Rare: blody diarrhea, duodenal ulcer, esophageal ulcer, gastrointestinal hemorrhage, hematemesis, hepatitis, peptic ulcer, stomach ulcer hemorrhage.

Hemic and Lymphatic System — Infrequent: ecchymosis; Rare: petechia, purpura.

ions — Frequent: QT interval prolongation (QTcF ≥450 msec)³. Nervous System — Frequent: emotional lability; Infrequent: akathisia, ataxia, balance disorder¹, bruxism¹, buccoglossal

syndrome, depersonalization, euphoria, hypertonia, libido increased, myoclonus, paranoid reaction; Rare: delusions Respiratory System — Rare: larynx edema.

Skin and Appendages — Infrequent: alopecia; Rare: purpuric rash. Special Senses — Frequent: taste perversion; Infrequent: mydriasis.

Urogenital System — *Frequent:* micturition disorder; *Infrequent:* dysuria, gynecological bleeding². ¹MedDRA dictionary term from integrated database of placebo controlled trials of 15,870 patients, of which 9,673 patients

Group term that includes individual MedDRA terms: cervix hemorrhage uterine, dysfunctional uterine bleeding, genital hemorrhage, menometrorrhagia, menorrhagia, metrorrhagia, polymenorrhea, postmenopausal hemorrhage, uterine hemorrhage, vaginal hemorrhage. Adjusted for gender. "Ot prolongation data are based on routine ECG measurements in clinical trials.

6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of fluoxetine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or evaluate

a causal relationship to drug exposure. ntary reports of adverse reactions temporally associated with fluoxetine that have been received since market introduction

Voluntary reports of adverse reactions temporally associated with fluoxetine that nave been received since market introduction and that may have no causal relationship with the drug include the following: anosmia, aplastic anemia, atrial fibrillation¹, cataract, cerebrovascular accident¹, cholestatic jaundice, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia (including, for example, a case of buccal-lingual-masticatory syndrome with involuntary tongue protrusion reported to develop in a 77-year-old female after 5 weeks of fluoxetine therapy and which completely resolved over the next few months following drug discontinuation), eosinophilic pneumonia¹, epidermal necrolysis, erythema multiforme, erythema nodosum, exfoliative dermatitis, galactorrhea, gynecomastia, heart arrest¹, hepatic failure/necrosis, hyperprolactinemia, hypoglycemia, hyposmia, immune-related hemolytic anemia, kidney failure, memory impairment, movement disorders developing in patients with risk factors including drugs associated with such reactions and worsening of pre-existing movement disorders, optic particities and and and and and another provide the providence of the providen neuritis, pancreatitis', pancytopenia, pulmonary embolism, pulmonary hypertension, QT prolongation, Stevens-Johnson syndrome, thrombocytopenia', thrombocytopenic purpura, ventricular tachycardia (including Torsades de Pointes–type rrhythmias), vaginal bleeding, and violent behav

lese terms represent serious adverse events, but do not meet the definition for adverse drug reactions. They are included their seriousness

7 DRUG INTERACTIONS As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic drug nent, etc.) is a po tion or enhanc

[See Dosage and Administration (2.9, 2.10), Contraindications (4.1), and Warnings and Precautions (5.2)]. 7.2 CNS Acting Drugs ant administration of fluoxetine and such drugs is required.

7.8 Drugs that Prolong the QT Interval Do not use fluoxetine in combination with thioridazine or pimozide. Use fluoxetine with caution in combination with other drugs that cause QT prolongation. These include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amidgarone, solalol); and others methodation medications (e.g., erytheratic biotectrice methodation mesvlate, probucio of tacrolimus). anzarhodanic, adolenady, specina taribuloacy (cg., cytonica), and analysis, adolenady, span adolenativ, outer analysis, additional antiarhythmic (e.g., amiodarone, sotald); and others (e.g., pentamidine, levomethadyi acetate, methadone, halofantine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Houxetine is primarily metabolized by CYP206. Concomitant treatment with CYP206 inhibitors can increase the concentration of fluoxetine. Conce mitant use of other highly protein-bound drugs can increase the concentration of fluoxetine [see .2), Warnings and Precautions (5.11), Drug Interactions (7.7), and Clinical Pharmacology (12.3)]. 8 USE IN SPECIFIC POPULATIONS

When using fluoxetine and olanzapine in combination, also refer to the Use in Specific Populations section of the package nsert for Symbyax.

B.1 Pregnancy

A regularity Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/ pregnancyregistry/antidepressants/

data from published observational studies, exposure to SSRIs, particularly in the month before delivery, has been d with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions (5.7) and

Available data from published epidemiologic studies and postmarketing reports over several decades have not established an increased risk of major birth defects or miscarriage. Some studies have reported an increased incidence of cardiovascular malformations; however, these studies results do not establish a causal relationship (*see Data*). There are risks associated with untreated depression in pregnancy and risks of persistent pulmonary hypertension of the newborn (PPHN) (*see Data*) and poor neonatal adaptation with exposure to selective serotonin reuptake inhibitors (SSRIs), including fluoxetine, during pregnancy (*see Clinical Considerations*).

In rats and rabbits treated with fluoxetine during the period of organogenesis, there was no evidence of developmental effects at doese up to 1.6 and 3.9 times, respectively, the maximum recommended human dose (MRHD) of 60 mg/day given to adolescents on a mg/m² basis. However, in other reproductive studies in rats, an increase in stillborn pups, a decrease in pup weight, and an increase in pup deaths early after birth occurred at doses that are 1.5 times (during gestation) and 0.97 time (during gestation and lactation) the MRHD given to adolescents on a mg/m² basis.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continue antidepressants. This finding is from a prospective, longitudinal study that followed 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy. pregnancy and postpartu

Maternal Adverse Reactions Use of fluoxetine in the month before delivery may be associated with an increased risk of postpartum hemorrhage [see Warnings and Precautions (5.7)].

Fetal/Neonatal adverse reaction

Veonates exposed to fluozetine and other SSRI or SNRIs late in the third trimester have developed complications requiring rolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoplycemia, hypotonia, hyperreflexia, tremors, jitteriness, irritability, and constant crying. These findings are consistent with either a direct toxic effect of SSRIs and SNRIs or possibly a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome *lisee Warnings and Precaution*

Data Human Data — It has been shown that SSRIs (including fluoxetine) can cross the placenta. Published epidemiological studies of pregnant women exposed to fluoxetine have not established an increased risk of major birth defects, miscarriage, and other adverse developmental outcomes. Several publications reported an increased incidence of cardiovascular malformations in children with in utero exposure to fluoxetine. However, these studies results do not establish a causal relationship. Methodologic limitations of these observational studies include possible exposure and outcome misclassification, lack of adequate controls, adjustment for confounders and confirmatory studies. However, these studies cannot definitely establish or exclude any drug-associated risk during negative. djustment for confounders and oc issociated risk during pregnancy.

Exposure to SSRIs, particularly later in pregnancy, may have an increased risk for PPHN, PPHN occurs in 1-2 per 1000 live births n the general population and is associated with substantial neonatal morbidity and mortality

Animal Data — In embryofetal development studies in rats and rabbits, there was no evidence of malformations or developmental variations following administration of fluoxetine at doses up to 12.5 and 15 mg/kg/day, respectively (1.6 and 3.9 times, respectively, the MRHD of 60 mg given to adolescents on a mg/m² basis [throughout organogenesis. However, in rat reproduction studies, an increase in stillborn pups, a decrease in pup weight, and an increase in pup deaths during the first 7 days postpartum occurred following maternal exposure to 12 mg/kg/day (1.5 times the MRHD given to adolescents on a mg/ m² basis) during gestation or 7.5 mg/kg/day (0.97 time the MRHD given to adolescents on a mg/m² and lactation. There was no evidence of developmental neurotoxicity in the surviving offspring of rats treated with 12 mg/kg/ day during gestation. The no-effect dose for rat pup mortality was 5 mg/kg/day (0.65 time the MRHD given to adolescents on

8.2 Lactation

Data from published literature report the presence of fluoxetine and norfluoxetine in human milk (see Data). There are reports of agitation, irritability, poor feeding, and poor weight gain in infants exposed to fluoxetine through breast milk *(see Clinical Considerations)*. There are no data on the effect of fluoxetine or its metabolites on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for fluoxetine and any potential adverse effects on the breastfed child from fluoxetine or the underlying maternal condition. Clinical Consider

fants exposed to fluoxetine should be monitored for agitation, irritability, poor feeding, and poor weight gain

A study of 19 nursing mothers on fluoxetine with daily doses of 10 mg to 60 mg showed that fluoxetine was detectable in 30%

of nursing infant sera (range: 1 to 84 ng/mL) whereas norfluoxetine was found in 85% (range: <1 to 265 ng/mL). 8.4 Pediatric Use tine in children - The efficacy of fluoxetine for the treatment of Maior Depressive Disorder was demonstrated in two 8- to 9-week placebo-controlled clinical trials with 315 pediatric outpatients ages 8 to \leq 18 *[see Clinical Studies (14.1)]*. The efficacy of fluoxetine for the treatment of OCD was demonstrated in one 13-week placebo-controlled clinical trial with 103

ediatric outpatients ages 7 to < 18 [see Clinical Studies (14.2)]. The safety and effectiv ness in pediatric patients < 8 years of age in Major Depressive Disorder and < 7 years of age in OCD ave not been established.

Fluoxetine pharmacokinetics were evaluated in 21 pediatric patients (ages 6 to \leq 18) with Major Depressive Disorder or OCD

See Clinical Pharmacology (12.3)]. The acute adverse reaction profiles observed in the 3 studies (N = 418 randomized; 228 fluoxetine-treated, 190 placebo-The balance decises relations produced production of the 2-standomized to each randomized, 22-or balance decises (120 photosoff treated) were generally similar to that observed in adult studies with fluxetine. The longer-term devises reaction profile observed in the 19-week Major Depressive Disorder study (N = 219 randomized; 100 fluxetine-treated, 110 placebo-treated) was also similar to that observed in adult rais with fluxetine. *Each* devises flexations (6, 1).

Mario reaction, including maria and hypomania, was reported in 6 (1 maria, 5 hypomania) out of 228 (2.6%) fluoxetine-treated patients and in 0 out of 190 (0%) placebo-treated patients. Mania/hypomania led to the discontinuation of 4 (1.8%) fluoxetine-treated patients from the acute phases of the 3 studies combined. Consequently, regular monitoring for the occurrence of omania is rec

As with other SSRIs, decreased weight gain has been observed in association with the use of fluoxetine in children and As winn other Sons, decreased weight gam has been observed in association with the use of inductement in clinical and addescent patients. After 19 weeks of treatment in a clinical trial, pediatric subjects treated with fluxetine gained an average of 1.1 cm less in height and 1.1 kg less in weight than subjects treated with placebo. In addition, fluxetine treatment was associated with a decrease in alkaline phosphatase levels. The safety of fluxetine treatment for pediatric patients has not been systematically assessed for chronic treatment longer than several months in duration. In particular, there are no studies that directly evaluate the longer-term effects of fluoxetine on the growth, development and maturation of children and adolescent efore, height and weight should be monitored periodically in pediatric patients receiving fluoxetine [see Warnings and Precautions (5.6)

Fluoxetine is approved for use in pediatric patients with MDD and OCD [see Box Warning and Warnings and Precautions (5.1)]. fering the use of fluoxetine in a child or adolescent must balance the potential risks with the clinical need ient has

1.25"H x 1.25"W

orn]), colloidal silicon dioxide, gelatin, sodium lauryl sulphate, FD&C Blue #1, FD&C Red #3, and titanium dioxide. In addition 0 mg capsules also contains D&C Yellow #10 and 10 mg capsules also contains FD&C Yellow #6. The capsules are printed ith edible ink containing black iron oxide, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.

12 CLINICAL PHARMACOLOGY

12.1 Mecha nism of Action Although the exact mechanism of fluoxetine is unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake

12.2 Pharmacodynamics

ies at clinically relevant doses in man have demonstrated that fluoxetine blocks the uptake of serotonin into human platelets Studies in onically location used on informative commonative man tookentic take of the optime of solution information protocols Studies in animals also suggest that fluxestime is a much more potential by the protocols are optime of a serio Antagonism of muscarinic, histaminergic, and q.-adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluxetine binds to these rane receptors from brain tissue much less potently in vitro than do the tricyclic drugs

12 3 Pharmacokinetics mic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine

rom 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours Food does not appear to affect the systemic bioavailability of fluoxetine, although it may delay its absorption by to 2 hours, which is probably not clinically significant. Thus, fluoxetine may be administered with or without food. Protein Binding — Over the concentration range from 200 ng/mL to 1,000 ng/mL, approximately 94.5% of fluxetine is bound in vitro to human serum proteins, including albumin and c1-glycoprotein. The interaction between fluxetine and other highly protein-bound drugs has not been fully evaluated, but may be important. *Engntiomers* — Fluxetine is a racemic instruct (50/50) of *R*-fluxetine and *S*-fluxetine enantiomers. In animal models,

both enantiomers are specific and potent serotonin uptake inhibitors with essentially equivalent pharmacologic activity S-fluoxetine enantiomer is eliminated more slowly and is the predominant enantiomer present in plasma at steady state. ogic activity. The Metabolism — Fluoxetine is extensively metabolized in the liver to norfluoxetine and a number of other unidentified metabolites. The only identified active metabolite, norfluoxetine, is formed by demethylation of fluoxetine. In animal models, S-norfluoxetine s a potent and selective inhibitor of serotonin uptake and has activity essentially equivalent to R- or S-fluoxetine. R-norfluoxetin significantly less potent than the parent drug in the inhibition of serotonin uptake. The primary route of elimination appears

Is defined in the bolt that in the part of the more minimum of source in parts. The primation point of the drug Variability in Metabolism — A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6). Such individuals are referred to as "poor metabolizers" of drugs such as debrisoquin, dextromethorphan, and the TCAs. In a study involving labeled and unlabeled enantiomers administered as a racemate, these ndividuals metabolized S-fluoxetine at a slower rate and thus achieved higher concentrations of S-fluoxetine. Consequer concentrations of S-norfluoxetine at steady state were lower. The metabolism of R-fluoxetine in these poor metaboliz pears normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of

appears nonnai, it is non-compared with monitoring in call some start some start some start of the internet concentration of the start Because fluoxetine's metabolism, like that of a number of other compounds including TCAs and other selective serotonin

suptake inhibitors (SSRIs), involves the CYP2D6 system, concomitant therapy with drugs also metabolized by this enzyme system (such as the TCAs) may lead to drug interactions [see Drug Interactions (7.7)]. Accumulation and Slow Elimination — The relatively slow elimination of fluoxetine (elimination half-life of 1 to 3 days after stration and 4 to 6 days after chronic administration) and its active metabolite, norfluoxetine (eli of 4 to 16 days after acute and chronic administration), leads to significant accumulation of these active species in chronic use and delayed attainment of steady state, even when a fixed dose is used [see Warnings and Precautions (5.14]]. After 30 days and desing of attainant of status generic provides and the status of the

by single-dose studies, because fluoxetine's metabolism is not proportional to dose. Northuoxetine, however, appears to have linear pharmacokinetics. Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days. Steady-state levels after prolonged dosing are similar to levels seen at 4 to 5 weeks. The long elimination half-lives of fluoxetine and norfluoxetine assure that, even when dosing is stopped, active drug substance will persist in the body for weeks (primarily depending on individual patient characteristics, previous dosing regimen, and length of previous therapy at discontinuation). This is of potential consequence when drug discontinuation is required or when drugs

cribed that might interact with fluoxetine and norfluoxetine following the discontinuation of fluoxetine 12.4 Specific Popula

liver Disease — As might be predicted from its primary site of metabolism, liver impairment can affect the elimination o uoxetine. The elim he elimination half-life of fluoxetine was prolonged in a study of cirrhotic patients, with a mean of pared with the range of 2 to 3 days seen in subjects without liver disease; norfluoxetine elimination was also 7.6 days com d with a mean duration of 12 days for cirrhotic patients compared with the range of 7 to 9 days in normal subjects This suggests that the use of fluoxetine in patients with liver disease must be approached with caution. If fluoxetine is a patients with liver disease, a lower or less frequent dose should be used (see Dosage and Administration (2.7) and Use in ecific Populations (8.6)]

parameter (0.0). asse — In depressed patients on dialysis (N = 12) fluoxetine administered as 20 mg once daily for 2 months. Renal Dis produced steady-state fluoxetine and norfluoxetine plasma concentrations comparable with those seen in pat renal function. While the possibility exists that renally excreted metabolities of fluxetine may accumulate to higher levels in patients with severe renal dysfunction use of a lower or less frequent dose is not routinely necessary in renally impaire

Geriatric Pharmacokinetics — The disposition of single doses of fluoxetine in healthy elderly subjects (> 65 years of age) did not differ significantly from that in younger normal subjects. However, given the long half-life and nonlinear disposition of the drug, a single-dose study is not adequate to rule out the possibility of altered pharmacokinetics in the elderly, particularly if hey have systemic illness or are receiving multiple drugs for concomitant diseases. The effects of age upon the metabolism of fluoxetine have been investigated in 260 elderly but otherwise healthy depressed patients (≥ 60 years of age) who received 20 mg fluoxetine for 6 weeks. Combined fluoxetine plus norfluoxetine plasma concentrations were 209.3 ng/m \pm 85.7 ng/mL at the end of 6 weeks. No unusual age-associated pattern of adverse reactions was observed in those elderl

Pediatric Pharmacokinetics (children and adolescents) — Fluoxetine pharmacokinetics were evaluated in 21 pediatric patients (10 children ages 6 to < 13. 11 adolescents ages 13 to < 18) diagnosed with Major Depressive Disorder or Obs patients (10 children ages 6 to < 13, 11 adorescents ages 1 st < 16) dragnosed with Major bepressive Disorder for Obsessive Compulsive Disorder (CCD). Fluxoetine 20 mg/day was administered for up to 62 days. The average steady-state concentrations of fluxoetine in these children were 2-fold higher than in adolescents (171 ng/mL and 86 ng/mL, respectively). The average norfluxetine steady-state concentrations in these children were 1.5-fold higher than in adolescents (195 ng/mL and 113 ng/mL, respectively). These differences can be almost entirely explained by differences in weight. No gender-associated difference in fluxetine pharmacokinetics was observed. Similar ranges of fluxetine and norfluxetine plasma concentrations were observed in another study in 94 pediatric patients (ages 8 to - 18) diagnosed with Major Depressive Disorder. Higher average steady-state fluxetine and norfluxetine concentrations were observed in children relative to adults; however, these concentrations within the range of concentrations plasmed in the adult ponulation. As in adults, fluxetine

these concentrations were within the range of concentrations observed in the adult population. As in adults, fluoxetine and etine accumulated extensively following multiple oral dosing; steady-state concentrations were achieved within 3 to weeks of dail

13 NONCLINICÁL TOXICOLOGY

13 NonclinicAL IOXIC/LIGH 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity — The dietary administration of fluoxetine to rats and mice for 2 years at doses of up to 10 mg/kg/day and 12 mg/kg/day, respectively (approximately 2.4 and 1.44 times, respectively, the maximum recommended human dose (MRHD) of 20 mg given to children on a mg/m² basis), produced no evidence of carcinogenicity. Mutagenicity — Fluoxetine and norfluoxetine have been shown to have no genotoxic effects based on the following assays: heteropic mutation across up in cultured to the hoerbordent mutation across up of up in cultured to the hoerbordent mutation across up of up in cultured to the hoerbordent mutation across up of up in cultured to the hoerbordent mutation across up of up in cultured to the hoerbordent mutation across up of up in cultured to the hoerbordent mutation across up of up in cultured to the hoerbordent mutation across up of up in cultured to the hoerbordent mutation across up of up of the culture steps characteristic across acros

bacterial mutation assay, DNA repair assay in cultured rat hepatocytes, mouse lymphoma assay, and in vivo sister chi exchange assay in Chinese hamster bone marrow cells.

Impairment of Fertility — Two fertility studies conducted in adult rats at doses of up to 7.5 mg/kg/day and 12.5 mg/kg/day approximately 0.97 and 1.6 times, respectively, the MRHD of 60 mg given to adolescents on a mg/m² basis) indicated that fluoxetine had no adverse effects on fertility. However, adverse effects on fertility were seen when juvenile rats were treated with fluoxetine [see Use in Specific Populations (8.4]).

13.2 Animal Toxicology and/or Pharmacology Phospholipids are increased in some tissues of mice, rats, and dogs given fluoxetine chronically. This effect is reversible after ation of fluoxetine treatment. Phospholipid accumulation in animals has been observed with many cationic amphiphilic s, including fenfluramine, imipramine, and ranitidine. The significance of this effect in humans is unknown. 4 CLINICAL STUDIES

Efficacy for fluoxetine was established for the

Acute and maintenance treatment of Major Depressive Disorder in adults, and children and adolescents (8 to 18 years) in 7 short-term and 2 long-term, placebo-controlled trials [see Clinical Studies 14.1]. Acute treatment of obsessions and compulsions in adults, and children and adolescents (7 to 17 years) with Obsessive

Compulsive Disorder (OCD) in 3 short-term placebo-controlled trials [see Clinical Studies (14.2)]. Acute and maintenance treatment of binge-eating and vomiting behaviors in adult patients with moderate to severe

Bulimia Nervosa in 3 short-term and 1 long-term, placebo-controlled trials [see Clinical Studies (14.3)]. Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients in 2 short-term, placebo-controlled trials [see Clinical Studies (14.4)].

[see Clinical Studies (14.4)].
Efficacy for fluoxetine and olarzapine in combination was established for the:
Acute treatment of depressive episodes in Bipolar I Disorder in adults, and children and adolescents (10 to 17 years) in 3 short-term, placebo-controlled trials.
Acute and maintenance treatment of treatment resistant depression in adults (18 to 85 years) in 3 short-term, placebo-controlled trials and 1 randomized withdrawal study with an active control.

consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration ules, and monitoring of clinical status [see Clinical Pharmacology (12.3)].

7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, li Description of the serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lib buspirone, amphetamines, tryptophan, and St. John's Wort) with fluoxetine increases the risk of serotonin syndrome. Monitor patients for signs and symptoms of serotonin syndrome, particularly during treatment initiation and dosage increases. If serotonin syndrome occurs, consider discontinuation of fluoxetine and/or concomitant serotonergic drugs [see Warnings and

7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDS, Aspirin, Warfarin)

ase by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAD or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SNRIs or SSRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when fluxestine is initiated or discussion of the discussion of th recautions (5.7)] ued *[see Warnings and F*

7.5 Electroconvulsive Therapy (ECT)

here are no clinical studies establishing the benefit of the combined use of ECT and fluoxetine. There have been rare reports f prolonged seizures in patients on fluoxetine receiving ECT treatment.

Or provinged services in patients on housement receiving Ec1 treatment.
7.6 Potential for Other Drugs to affect Fluoxetine
Drugs Tightly Bound to Plasma Proteins — Because fluoxetine is tightly bound to plasma proteins, adverse effects may result from displacement of protein-bound fluoxetine by other tightly-bound drugs [see Clinical Pharmacology (12.3)].
7.7 Potential for Fluoxetine to affect Other Drugs
Drugs Tightly Bound to Plasma Proteins — Because fluoxetine is tightly bound to plasma proteins, adverse effects may result from displacement of protein-bound fluoxetine by other tightly-bound drugs [see Clinical Pharmacology (12.3)].
7.7 Potential for Fluoxetine to affect Other Drugs
Pimozide — Concomitant use in patients taking pimozide is contraindicated. Pimozide can prolong the QT interval. Clinical studies of innervise the level of pimozide through inhibition of CYP2DB. Fluoxetine can also prolong the QT interval. Clinical studies of innervise the devel of pimozide through inhibition of CYP2DB. pimozide with other antidepressants demonstrate an increase in drug interaction or QT prolongation. While a specific study with pimozide and fluoxetine has not been conducted, the potential for drug interactions or QT prolongation warrants restricting the concurrent use of pimozide and fluoxetine [see Contraindications (4.2), Warnings and Precautions (5.11), and Drug Interactions (7.8)].

Thioridazine — Thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued, because of the risk of QT Prolongation [see Contraindications (4.2), Warnings and Precautions (5.11), and

In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg and dose of thioridazine produced a 2.4-fold higher Cmm and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared with the rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of CYP2D6 isozyme activity. Thus, this study suggests that drugs which inhibit CYP2D6, such as certain SSRIs, including fluxetine, will produce elevated plasma levels of thio

inordazine administration produces a dose-related prolongation of the QT interval, which is associated with serious entricular arrhythmias, such as Torsades de Pointes-type arrhythmias, and sudden death. This risk is expected to increase with fluoxetine-induced inhibition of thioridazine metal

Drugs Metabolized by CYP2D6 — Fluoxetine inhibits the activity of CYP2D6, and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propatenone, flexalinide, and others) should be approached with caution. Therapy with medications that are predominantly ized by the CYP2D6 system and that have a relatively narrow therapeutic index (see list below) should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. Thus, his/her dosing requirements resemble those of poor metabolizers. If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for decreased dose of the original medication should be considered. Drugs with a narrow therapeutic index represent the greatest concern (e.g., flecainide, propafenone, vinblastine, and TCAs). Due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued [see Contraindications (4.2)]

ricyclic Antidepressants (TCAs) — In 2 studies, previously stable plasma levels of impramine and desipramine h greater than 2- to 10-fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or longer after fluoxetine is discontinued. Thus, the dose of TCAs may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued *[see Warnings and* Precautions (5.2) and Clinical Pharmacology (12.3)].

Perzodiazepines — The half-life of concurrently administered diazepam may be prolonged in some patients [see Clinical Pharmacology (12.3)]. Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and in further psychomotor performance decrement due to increased alprazolam levels.

Antipsychotics — Some clinical data suggests a possible pharmacodynamic and/or pharmacokinetic interaction between SSRIs and antipsychotics. Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant

fluoxetine. Anticonvulsants — Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment. Lithium — There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with fluoxetine. Cases of lithium toxicity and increased serotonergic effects have been reported. Lithium levels should be monitored when these drugs are administered concomitantly *[see Warnings and Precautions (5.2)]*. Drugs Tightly Bound to Plasma Proteins — Because fluoxetine is tightly bound to plasma proteins, the administration of fluoxetine to a patient taking another drug that is tightly bound to protein (e.g., Coumadin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect *[see Clinical Pharmacology (12.3)]*. Drugs Metabolized by CYP3A4 — In an *in vivo* interaction study involving coadministration of fluoxetine in et (AVP3A4 substrate). Dan in grame terfenadine (a CVP3A4 substrate). Dan in grame atterfance in concentrations occurred with concomitant fluoxetine.

terfenadine (a CYP3A4 substrate), no increase in plasma terfenadine concentrations occurred with concomitant fluoxetine. Additionally, *in vitro* studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, claspride, and midazolam. These data indicate that fluoxetine's extent of inhibition of CYP3A4 activity is not likely the ad-oblication of the metabolism. to be of clinical significance

Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is

When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert

been observed following exposure of juvenile rats to fluoxetine from weaning through maturity. Oral adm istration of luoxetine to rats from weaning postnatal day 21 through adulthood day 90 at 3 mg/kg/day, 10 mg/kg/day, or 30 mg/kg/day was associated with testicular deceneration and necrosis, epididymal vacuolation and hypospermi

rmia (at 30 mg/kg/day corresponding to plasma exposures [AUC] approximately 5 to 10 times the average AUC in pediatric patients at the MRHD of 20 mg/day), increased serum levels of creatine kinase (at AUC as low as 1 to 2 times the average AUC in pediatric patients at the MRHD of 20 mg/day), Skeletal muscle degeneration and necrosis, decreased femur length/growth and body weight gain (at AUC 5 to 10 times the average AUC in pediatric patients at the MRHD of 20 mg/ day). The high dose of 30 mg/kg/day exceeded a maximum tolerated dose. When animals were evaluated after a drug-free period (up to 11 weeks after cessation of dosing), fluoxetine was associated with neurobehavioral abnormalities sed reactivity at AUC as low as approximately 0.1 to 0.2 times the average AUC in pediatric patients at the nent (decreased mating at all doses and MRHD and learning deficit at the high dose), and reproductive functional impairment (decreased mating at all doses a impaired fertility at the high dose). In addition, the testicular and epididymal microscopic lesions and decreased spe concentrations found in high dose group were also observed, indicating that the drug effects on reproductive organs are irreversible. The reversibility of fluoxetine-induced muscle damage was not assessed.

bese fluoxetine toxicities in iuvenile rats have not been observed in adult animals. Plasma exposures (AUC) to fluoxetine in e rats receiving 3 mg/kg/day, 10 mg/kg/day, or 30 mg/kg/day doses in this study are approximately 0.1 to 0.2 o 10 times, respectively, the average exposure in pediatric patients receiving the MRHD of 20 mg/day. Rat e ximately 0.1 to 0.2. 1 to 2. and 5 to 10 times, respe to the major metabolite, norfluoxetine, are approximately 0.3 to 0.8, 1 to 8, and 3 to 20 times, respectively, the pediatric sure at the MRHD

A specific effect on bone development was reported in juvenile mice administered fluoxetine by the intraperitoneal route to A special circle on cone de etaplinen Naz rapótico in foromit tince administrative accumistrative of the interperiod of a terminate of a verse of the set tion in patients 10 to 17 years of age have been established for the acute treatment of dep with Bipolar I Disorder. Safety and effectiveness of fluoxetine and olanzapine in combination in patients less than 10 years of age have not been established

8.5 Geriatric Use

tine clinical trials included 687 patients > 65 years of age and 93 patients > 75 years of age. The efficacy in geniatric US fluo Obtained and the initial initial of the set of the s ation in geriatric patients, [see Clinical patients, but orgater sensitivity of some older individuals cannot be ruled out. SNBIs and SSBIs including fluc associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse reaction [see Warnings and Precautions (5.9)]. Clinical studies of olarizations and frequencies (5.9)].

e whether they respond differently from younger patients 8.6 Hepatic Impairment

n subjects with cirrhosis of the liver, the clearances of fluoxetine and its active metabolite, norfluoxetine, were decreased, thus sing the elimination half-lives of these substances. A lower or less frequent dose of fluoxetine should be used in patients rrhosis. Caution is advised when using fluoxetine in patients with diseases or conditions that could affect its metabolism ation (2.7) and Clinical Pharmacology (12.4)] see Dosage and Adn

9 DRUG ABUSE AND DEPENDENCE

9.3 Dependence

tine has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical noncodine native to consistent systematically submitted on native to materials, for the potential to double, to distinct, or produce dependence. While the premarketing clinical experience with fluxetime did not reveal any tendency for a withdrawal syndrome or any drug seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CMS active drug will be misused, diverted, and/or abused once marketed. Consequently, ealthcare providers should carefully evaluate patients for history of drug abuse and follow such patients closely, ob hem for signs of misuse or abuse of fluoxetine (e.g., development of tolerance, incrementation of dose, drug-seeking behavior 10 OVERDŐSAGE

e following have been reported with fluoxetine overdosage

Seizures, which may be delayed, and altered mental status including coma. Cardiovascular toxicity, which may be delayed, including QRS and QTc interval prolongation, wide complex tachyarrhythmias, torsade de pointes, and cardiac arrest. Hypertension most commonly seen, but rarely can see


sion alone or with co-ingestants including alcohol. erotonin syndrome (patients with a multiple drug overdosage with other pro-serotonergic drugs may have a higher risk

ointestinal decontamination with activated charcoal should be considered in patients who present early after a fluoxetine

Consider contacting a Poison Center (1-800-221-2222) or a medical toxicologist for additional overdosage management

11 DESCRIPTION

ules, USP are a selective serotonin reuptake inhibitor for oral administration. It is designated (\pm) -N-methyl 3-phenyl-3-[(α,α,α -trifluoro-p-tolyl)oxy]propylamine hydrochloride and has the empirical formula of C₁,H₂F₂NO•HCI. Its cular weight is 345.79. The structural formula is:



Fluoxetine hydrochloride. USP is a white to off-white crystalline powder with a solubility of 14 mg/mL in water Each capsule contains fluoxetine hydrochloride equivalent to 10 mg (32.3 µmol), 20 mg (64.7 µmol), or 40 mg (129.3 µmol) of fluoxetine. The capsules also contain the following inactive ingredients: pregela

14.1 Major Depressive Disorder

Daily Dosing Adult — The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of Major Depressive Disorder. Fluoxetine was shown to be significantly more effective than placebo as measured by the Hamilton Depression Rating Scale (HAM-D). Fluoxetine was also significantly more effective than placebo as measured by the Hamilton Depression Rating Scale (HAM-D). Fluoxetine was also significantly more effective than placebo as measured by the Hamilton Depression Rating Scale (FAM-D). Fluoxetine was also significantly more effective than placebo have shown fluoxetine 20 mg daily to be effective in the treatment of elderly patients (≥ 60 years of age) with Major Depressive Disorder. In these studies, fluoxetine produced a significantly higher rate of response and remission as defined, respectively, by a 50% decrease in the HAM-D. Score and a total endpoint HAM-D score of sale. Fluoxetine was well tolerated and the rate of treatment discontinuations due to adverse reactions did not differ between fluoxetine (12%) and placebo (9%).

Pediatric (children and adolescents) — The efficacy of fluoxetine 20 mg/day in children and adolescents (N = 315 randomized; 170 children ages 8 to < 13, 145 adolescents ages 13 to \leq 18) was studied in two 8- to 9-week placebo-controlled clinica sed outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of Major trials in depre ive Disorder.

n both studies independently, fluoxetine produced a statistically significantly greater mean change on the Childhood Depression Rating Scale-Revised (CDRS-R) total score from baseline to endpoint than did placebo

Subgroup analyses on the CDRS-R total score did not suggest any differential responsiveness on the basis of age or gender. nance Treatment Mainte

A study was conducted involving depressed outpatients who had responded (modified HAMD-17 score of < 7 during each of the

A study was conducted involving depressed outpatients who had responded (modified HAMD-17 score of \leq 7 during each of the last 3 weeks of open-label treatment and absence of Major Depressive Disorder by DSM-III-R criteria) by the end of an initial 12-week open-treatment phase on fluxetine 20 mg/day. These patients (N=290) were randomized to continuation on double-blind fluxetine 20 mg/day or placebo. At 38 weeks (50 weeks total), a statistically significantly lower relapse rate (defined as symptoms sufficient to meet a diagnosis of Major Depressive Disorder for 2 weeks or a modified HAMD-17 score of \leq 14 for 3 weeks) was observed for patients taking fluxetine compared with those on placebo. An additional maintenance study was conducted involving adult outpatients meeting DSM-IV criteria for Major Depressive Disorder) for 3 consecutive weeks at the end of 13 weeks of open-label treatment with fluxetine 20 mg orce daily. These patients (N=290) double double-blind fluxetine 20 mg once daily, these patients were randomized to double-blind no. enc-weekly continuation treatment with fluxetine delayed-release capsules 90 mg once weekly, fluxetine 20 mg once daily, or placebo. Fluxetine 20 mg once daily demonstrated superior efficacy (having a significantly longer time to relapse of depressive symptoms) compared with placebo

demonstrated superior efficacy (having a significantly longer une or leapse or opposed of 25 weeks. 14.2 Obsessive Compulsive Disorder Adult — The effectiveness of fluxatine for the treatment of Obsessive Compulsive Disorder (OCD) was demonstrated in two 13-week, multicenter, parallel group studies (Studies 1 and 2) of adult outpatients who received fixed fluxatine doese of 20 mg/day, 40 mg/day, or 60 mg/day (on a once-a-day schedule, in the morning) or placebo. Patients in both studies had moderate to severe OCD (DSM-III-R), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS, total score) ranging from 22 to 26. In Study 1, patients receiving fluxatine experienced mean reductions of approximately 4 to 6 units on the YBOCS total score, compared with a 1-unit reduction for placebo patients. In Study 2, patients receiving fluxatine experienced mean reductions of approximately 4 to 9 units on the YBOCS total score, compared with a 1-unit reduction for placebo patients. While there was no indication of a dose-response relationship for effectiveness in Study 1, a dose-response relationship was observed in Study 2, with numerically better responses in the 2 higher dose groups. The following table provides the outcome classification by treatment group on the Clinical Global Impression (CGI) improvement scale for Studies 1 and 2 combined: **Table 6**

Outcome Classification (%) on CGI Improvement Scale for Completers in Pool of Two OCD Studies

		Fluoxetine		
Outcome Classification	Placebo	20 mg	40 mg	60 mg
Worse	8%	0%	0%	0%
No change	64%	41%	33%	29%
Minimally improved	17%	23%	28%	24%
Much improved	8%	28%	27%	28%
Very much improved	3%	8%	12%	19%

Exploratory analyses for age and gender effects on outcome did not suggest any differential responsiveness on the basis of age or sex.

tric (children and adolescents) — In one 13-week clinical trial in pediatric patients (N = 103 randomized; 75 children ages 7 to < 13, 28 adolescents ages 13 to < 18) with OCD (DSM-IV), patients received fluoxetine 10 mg/day for 2 weeks, followed by 20 mg/day to r 2 weeks. The dose was then adjusted in the range of 20 mg/day to 60 mg/day on the basis of clinical response and tolerability. Fluoxetine produced a statistically significantly greater mean change from baseline to endpoint than did placebo as measured by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS).

Subgroup analyses on outcome did not suggest any differential responsive ness on the basis of age or gende 14.3 Bulimia Nervosa

he effectiveness of fluoxetine for the treatment of bulimia was demonstrated in two 8-week and one 16-week, multicenter The effective state in the basis of the treatments meeting ISSM-III-R criteria for bulimia. Patients in the 8-week studies received either 20 mg/day or 60 mg/day of fluxetine or placebo in the morning. Patients in the 16-week study received a fixed fluxetine does of 60 mg/day (once a day) or placebo. Patients in these 3 studies had moderate to severe bulimia with median binge-eating and vomiting frequencies ranging from 7 to 10 per week and 5 to 9 per week, respectively. In these 3 studies, fluxetine 60 mg, but not 20 mg, was statistically significantly superior to placebo in reducing the number of binge-eating and vomiting encoder one week. The deticitable significantly superior to placebo in the nue respectively. In these 3 studies, fluxetine 60 mg, but not 20 mg, was statistically significantly superior to placebo in the nue respectively. In these 3 studies, fluxetine 60 encoder one week. The deticated is a studies of the form week and 5 to 9 per week, respectively. In these 3 studies, fluxetine 60 encoder one are the studies of the form of the form of the form of the studies of the deticated before the studies of the episodes per week. The statistically significantly superior effect of 60 mg versus placebo was present as early as Week 1 and persisted throughout each study. The fluoxetine-related reduction in bulimic episodes appeared to be independent of baseline depression as assessed by the Hamilton Depression Rating Scale. In each of these 3 studies, the treatment effect, as measured by differences between fluoxetine 60 mg and placebo on median reduction from baseline in frequency of bulimic behaviors a

Use in Specific Populations

Sexual Dysfunction

Use of Concomitant Medications

ion of Treatment

Pregnancy — Advise pregnant women to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with fluoxetine.

Advise patients that fluoxetine use later in pregnancy may lead to increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN) [see Use in Specific Populations (8.1)].

Advise women that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to fluoxetine during pregnancy [see Use in Specific Populations (8.1)].

Lactation — Advise breastfeeding women using fluoxetine to monitor infants for agitation, irritability, poor feeding and poor weight gain and to seek medical care if they notice these signs [see Use in Specific Populations (8.2)].

Pediatric Use of fluoxetine - Fluoxetine is approved for use in pediatric patients with MDD and OCD [see Box Warning and Warnings and Precautions (5.1)]. Limited evidence is available concerning the longer-term effects of fluoxetine on the development and maturation of children and adolescent patients. Height and weight should be monitored periodically in pediatric patients receiving fluoxetine (see Warnings and Precautions (5.6) and Use in Specific Populations (8.4)].

Pediatric Use of fluoxetine and olanzapine in combination-Safety and efficacy of fluoxetine and olanzapine in combination in patients 10 to 17 years of age have been established for the acute treatment of depressive episodes associated with Bipolar i Disorder [see Warnings and Precautions (5.16) and Use in Specific Populations (8.4)].

All trademarks are the property of their respective owners.

Dispense the Medication Guide available at: https://radhapharm.com/medication-guide

Manufactured by: ScieGen Pharmaceut Hauppauge, NY 11788 USA euticals Ind

Radha Pharmaceuticals, Hauppauge, NY 11788 USA

Revised: 3/2024

Rx only

12491-PM-1342 PIL Fluoxetine Caps 10, 20 and 40 mg (ScieGen).indd 2